Searched for
CHRONIC MEDICINE PORTFOLIO
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 27%, according to analystsWe are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- 5 mid-cap stocks from different sectors with an upside potential of 13 to 24% in one year, according to analystsWhen mid-caps were rising, every concern on valuation was treated as unnecessary caution. Investors who advised patience were told they wer...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Volatility as opportunity, depends on framework of mind: 5 mid-caps from different sectors with upside potential of up to 31%The Indian stock market is no longer correcting only because of sentiment. It is now adjusting to the possibility of weaker numbers in the ...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsHas a peace deal been agreed on by the US and Iran? Will the fragile ceasefire hold? No one can answer these questions with any certainty. ...
- Gene therapy for cholesterol: Initial test results cheerA new gene editing medicine, VERVE-102, offers hope for millions with heart conditions. Eli Lilly's drug showed significant reductions in b...
- Kerala’s healthcare gold rush: How private equity is reshaping hospitals and raising fears over costsPrivate equity funds are pouring hundreds of millions of dollars into Kerala’s healthcare sector, reshaping a system long dominated by inde...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Venus Remedies gets Saudi FDA approval for speciality oncology therapyVenus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi ...
- HAB Pharma merges Signature Phytochemicals, eyes Rs3,000 crore revenue by 2030HAB Pharma and Signature Phytochemicals have merged, creating a consolidated entity with a turnover of Rs600 crore. This strategic move aim...
- Time to take the first step to become a contrarian? 4 mid-cap stocks from different sectors with upside potential up to 21%As the risk created by the US-Iran war keeps crude oil prices elevated, the list of stocks where investors can deploy fresh money with comf...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%In these times of geopolitical stress, how will things pan out for the Indian market? Will it be a standalone underperformer? Or is it just...
- Demonetisation: People stock up on medicines to get rid of old notesAWACs found that anti-diabetic, cardiovascular and BP drugs have shown a significant increase in sales as compared to corresponding period ...
- Chronic illness sees a spurt in business opportunity for pharma marketAccording to data from AIOCD, the Indian pharma market has grown at a compound annual growth rate of 3.3% in volume terms in the past five ...
Load More
